Tonix Pharma Q2 2023 net loss $28.4M; completes acquisition of two migraine products

Tonix Pharmaceuticals Holding Corp.

2023-Q2 EPS reported -$5.88

Net loss $28.4M ($2.68/sh) vs $27.4M ($7.64/sh) in Q2 2022; R&D expense rose to $22.0M from $16.6M.
Cash & equivalents $25.6M at June 30, down from $120.2M at Dec 31, 2022; raised $7.0M in Aug 2023 offering.
Closed acquisition of Zembrace SymTouch and Tosymra from Upsher-Smith for $15M plus $10M inventory; trailing sales ~$30M.
Enrolled four CNS trials: RESILIENT fibromyalgia (Q4 topline), PREVAIL Long COVID (Q3), PREVENTION chronic migraine (Q4), UPLIFT MDD (Q4).

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tonix Pharmaceuticals Holding Corp. reported financial results for second quarter ended June 30, 2023.

Period: second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended June 30, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001387131-23-009623

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.